Space News from SpaceDaily.com
Pharma giant AstraZeneca takes China probes 'very seriously'
ADVERTISEMENT


London, Nov 12 (AFP) Nov 12, 2024
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention of its China boss.

"We take the matters in China very seriously," chief executive Pascal Soriot said in a statement contained in the group's latest earnings release that revealed a small rise in net profit.

"If requested we will fully cooperate with the authorities. We remain committed to delivering innovative life-changing medicines to patients in China," he added.

The group last week confirmed Leon Wang, president of AstraZeneca China, had been detained.

China is a key market for AstraZeneca, developer of a Covid-19 jab widely administered throughout the world during the coronavirus pandemic.

AstraZeneca on Tuesday noted that China accounted for about 12 percent of its global revenues in the third quarter. Sales in the country jumped 15 percent in the July-September period.

"The company is aware of a number of individual investigations by the Chinese authorities into current and former AstraZeneca employees," the drugs giant added in the latest statement.

"To the best of the company's knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches."

AstraZeneca said it "has not received any notification that it is itself under investigation".

The probes involved five current and former employees of the firm -- all with Chinese citizenship -- which are being led by authorities in the southern city of Shenzhen, according to Bloomberg.

One investigation related to the firm's collection of patient data, which authorities suspect may have breached Chinese privacy laws, the financial newswire also reported, citing people with knowledge of the situation.

Another probe related to imports of a liver cancer drug that had not been approved in mainland China, according to Bloomberg.

UK-headquartered AstraZeneca has 90,000 employees globally.

Multinationals have faced an increasingly-difficult business environment in China in recent years, industry groups say, citing a lack of transparency on data laws and prolonged detentions of employees.

- US investment -


AstraZeneca on Tuesday added that profit after tax rose four percent in the third quarter to $1.4 billion from a year earlier.

Total revenue jumped 18 percent to $13.6 billion, "reflecting the increasing demand for our medicines across oncology, biopharmaceuticals and rare disease", said Soriot.

The group also announced $2-billion of new investment in its main market, the United States.

Shares in AstraZeneca were down 1.3 percent in midday deals on London's top-tier FTSE 100 index, which was trading one percent lower overall.

Its shares fell sharply when reports of Wang's detention emerged earlier this month, wiping billions of dollars off its valuation.

AstraZeneca's profits "upgrade puts the Chinese probe in perspective", noted Derren Nathan, head of equity research at Hargreaves Lansdown.

burs-bcp/ajb/db


ADVERTISEMENT





Space News from SpaceDaily.com
Europe's troubled Vega-C rocket launches after delays
China launches third batch of 18 communication satellites
ESA launches spacecraft that will eventually create artificial solar eclipse

24/7 Energy News Coverage
Quantum materials research at University of Oldenburg secures ERC Grant
A film capacitor that can take the heat
NASA advances sustainable aircraft testing with innovative wing design

Military Space News, Nuclear Weapons, Missile Defense
Muon Space secures contract to enhance space-based environmental monitoring
Lavrov says Russia ready to defend itself through 'any means'
Umbra chosen for NRO Strategic Enhancements Stage III to boost SAR capabilities

24/7 News Coverage
Researchers use citizen scientist data to explore blue auroras in Japan
Recent global temperature surge amplified by record-low planetary albedo
Will the Ross Ice Shelf melt



All rights reserved. Copyright Agence France-Presse. Sections of the information displayed on this page (dispatches, photographs, logos) are protected by intellectual property rights owned by Agence France-Presse. As a consequence, you may not copy, reproduce, modify, transmit, publish, display or in any way commercially exploit any of the content of this section without the prior written consent of Agence France-Presse.